BriaCell Shows Phase 2 Survival Wins, Phase 3 Enrollment On Track
BriaCell’s whole‑cell breast‑cancer vaccine, Bria‑IMT, shows significant overall‑survival gains in Phase 2 and hits Phase 3 enrollment milestones, positioning the company for potential accelerated approval and market launch.
3 minutes to read